Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review

Carmelo Pirone, Claudia Mendoza-Pinto, Daniëlle A van der Windt, Ben Parker, Miriam O Sullivan, Ian N Bruce, Carmelo Pirone, Claudia Mendoza-Pinto, Daniëlle A van der Windt, Ben Parker, Miriam O Sullivan, Ian N Bruce

Abstract

Background: The clinical outcomes following rituximab (RTX) treatment in patients with systemic lupus erythematosus (SLE) is highly variable. We aimed to identify predictive and prognostic factors associated with RTX therapy outcomes in patients with SLE.

Methods: Studies in adults and paediatric patients with SLE were included. We included randomized clinical trials (RCTs) for predictors of differential treatment effect and cohort studies for potential prognostic factors in patients treated with RTX (global clinical, cutaneous and renal either response or relapse, and side effects). Methodological quality was assessed using Cochrane Collaboration Risk of Bias tool and the Quality In Prognosis Studies Tool (QUIPS) for RCTs and cohort studies, respectively. The quality of subgroup analyses testing predictors of differential treatment response was also evaluated. A best evidence synthesis was performed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.

Results: Sixteen articles were included (3 from 2 RCTs and 13 from 6 cohort studies). The overall quality of evidence (QoE) was low to very low (GRADE framework). QoE for predictive factors based on RCTs analysing sociodemographic variables, was rated very low due to the lack of interaction tests, limited power of subgroup analyses, study limitations, and imprecisions. Disease-related factors including clinical phenotype and severity, baseline anti-ENA antibodies and anti-Ro antibodies, interleukin (IL) 2/21 single nucleotide polymorphism (SNP), as well as post-RTX complete B-cell depletion and earlier B-cell repopulation showed some evidence for prognostic value, but were rated low to very low QoE because of early phase of investigation (exploratory analysis), insufficient adjustment for confounding in most studies, high risk of bias, inconsistency, and imprecisions.

Conclusions: To date, studies addressing prognostic factors are hypothesis generating and cannot be used to make any specific recommendations for routine clinical practice. A number of potential predictors/prognostic factors were identified, which require to be validated as being specific for response to RTX therapy and to enable more personalised use of this agent.

Keywords: Prognosis; Rituximab; Systematic review; Systemic lupus erythematosus.

Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
Study flow diagram detailing the literature search.
Fig. 2
Fig. 2
Risk of bias summary of RCTs included.

References

    1. Hamburg M.A., Collins F.S. The path to personalized medicine. N Engl J Med. 2010;363:301–304.
    1. Trusheim M.R., Berndt E.R., Douglas F.L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6:287–293.
    1. Rothwell P.M., Mehta Z., Howard S.C., Gutnikov S.A., Warlow C.P. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet. 2005;365:256–265.
    1. Tsokos G.C. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–2121.
    1. Cambridge G., Perry H.C., Nogueira L., Serre G., Parsons H.M., De La Torre I. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun. 2014;50:67–76.
    1. Furtado J., Isenberg D.A. B cell elimination in systemic lupus erythematosus. Clin Immunol. 2013;146:90–103.
    1. Duxbury B., Combescure C., Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus. 2013;22:1489–1503.
    1. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–233.
    1. Rovin B.H., Furie R., Latinis K., Looney R.J., Fervenza F.C., Sanchez-Guerrero J. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215–1226.
    1. Hahn B.H., McMahon M.A., Wilkinson A., Wallace W.D., Daikh D.I., Fitzgerald J.D. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797–808.
    1. Bertsias G.K., Tektonidou M., Amoura Z., Aringer M., Bajema I., Berden J.H.M. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–1782.
    1. Albert D., Dunham J., Khan S., Stansberry J., Kolasinski S., Tsai D. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67:1724–1731.
    1. Vital E.M., Dass S., Buch M.H., Henshaw K., Pease C.T., Martin M.F. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011;63:3038–3047.
    1. Peduzzi P., Concato J., Kemper E., Holford T.R., Feinstein A.R. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373–1379.
    1. Higgins JP, Green S. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. . Published 2011. Accessed 16.06.2016.
    1. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
    1. Mendoza-Pinto C, Pirone C, van der Windt DA, Parker B, Bruce IN. Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review. Sem Arthritis Rheum 2017 Feb 9. pii: S0049-0172(16)30337-7. [Epub ahead of print], this issue.
    1. Higgins J.P., Altman D.G., Gotzsche P.C., Juni P., Moher D., Oxman A.D. The Cochrane Collaboration׳s tool for assessing risk of bias in randomised trials. Br Med J. 2011;343:d5928.
    1. Pincus T., Miles C., Froud R., Underwood M., Cames D., Taylor S. Methodological criteria for the assessment of moderators in systematic reviews of randomised controlled trials: a consensus study. BMC Med Res Methodol. 2011;11:14.
    1. Hayden J., van der Windt D.A., Cartwright J.L., Cote P., Bombardieri C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158:280–286.
    1. Guyatt G.H., Oxman A.D., Kunz R., Atkins D., Brozek J., Vist G.E. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64:395–400.
    1. Guyatt G.H., Oxman A.D., Schunemann H.J., Tugwell P., Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–382.
    1. Huguet A., Hayden J., Stinson J., McGrath P.J., Chambers C.T., Tougas M.A. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Syst Rev. 2013;2:71.
    1. Balshem H., Helfand M., Schunemann H.J., Oxman A.D., Kunz R., Brozek J. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–406.
    1. Tew G.W., Rabbee N., Wolslegel K., Hsieh H.J., Monroe J.G., Behrens T.W. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010;19:146–157.
    1. Carter L.M., Isenberg D.A., Ehrenstein M.R. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013;65:2672–2679.
    1. Lazarus M.N., Turner-Stokes T., Chavele K.M., Isenberg D.A., Ehrenstein M.R. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford) 2012;51:1208–1215.
    1. Lindholm C., Borjesson-Asp K., Zendjanchi K., Sundqvist A.C., Tarkowski A., Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35:826–833.
    1. Catapano F., Chaudhry A.N., Jones R.B., Smith K.G., Jayne D.W. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25:3586–3592.
    1. Dias S.S., Rodriguez-Garcia V., Nguyen H., Pericleous C., Isenberg D. Longer duration of B cell depletion is associated with better outcome. Rheumatology (Oxford) 2015;54:1876–1881.
    1. Fernandez-Nebro A., de la Fuente J.L., Carreno L., Izquierdo M.G., Tomero E., Rua-Figueroa I. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. 2012;21:1063–1076.
    1. Jonsdottir T., Gunnarsson I., Mourao A.F., Lu T.Y., van Vollenhoven R.F., Isenberg D. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford) 2010;49:1502–1504.
    1. Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., Isenberg D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis. 2007;66:1259–1262.
    1. Robledo G., Davila-Fajardo C.L., Marquez A., Ortego-Centeno N., Callejas Rubio J.L., de Ramon G.E. Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases. DNA Cell Biol. 2012;31:1486–1491.
    1. Robledo G., Marquez A., Davila-Fajardo C.L., Ortego-Centeno N., Rubio J.L., Garrido E.R. Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients. DNA Cell Biol. 2012;31:1671–1677.
    1. Marquez A., Davila-Fajardo C.L., Robledo G., Rubio J.L., de Ramon G.E., Garcia-Hernandez F.J. IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. Mol Biol Rep. 2013;40:4851–4856.
    1. Vital E.M., Wittmann M., Edward S., Md Yusof M.Y., MacIver H., Pease C.T. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol. 2015;67:1586–1591.
    1. Cuppen B.V., Welsing P.M., Sprengers J.J., Bijlsma J.W., Marijnissen A.C., van Laar J.M. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology (Oxford) 2016;55:826–839.
    1. Menon M., Blair P.A., Isenberg D.A., Mauri C. A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity. 2016;44:683–697.
    1. Ezeonyeji A.N., Isenberg D.A. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology (Oxford) 2012;51:476–481.
    1. Gracia-Tello B., Ezeonyeji A., Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017;4:e000182.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe